A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions.
Xue YuXinyue WangFusui JiWenduo ZhangChenguang YangFeng XuFang WangPublished in: Cardiovascular drugs and therapy (2021)
In this prospective study, the DCB only strategy for de novo lesion was non-inferior to the new-generation DES in terms of 9-month late lumen loss.